article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Adams, on a first-in-human study of ELU001, a targeted c’dot drug conjugate, in subjects with folate receptor α (frα) overexpressing solid tumours, and Groothuis on the non-clinical pharmacology of the MET-targeting ADC BYON3521. CCO & Co-Founder, ATUM, on: “Using machine learning to predict protein expression”.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Panelists include: John Anderson, PhD, GOSHCC Professor, Honorary Consultant Oncologist, Experimental Paediatric Oncology, University College London Michael Hudecek, MD, Professor, Cellular Immunotherapy of Malignant Diseases, University of Wuerzburg Sebastian Kobold, MD, Professor, Clinical Pharmacology, Klinikum der Universität München.